Another striking difference between Vk*MYC and human MM is the higher prevalence of mutations of Dusp2 (a negative regulator of Stat3 pathway39), Pim1, Kdm6a, Ncor1 and Pten (a negative regulator of mTORC pathway) and low incidence of mutations of Ras (an activator of MAPK and mTORC140 pathways) in the mouse. This evidence concerns the gene MYC and Miyoshi myopathy.